Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patient

International Clinical Psychopharmacology

Volumn 21, Issue 3, 2006, Pages 181-184

  Papadimitriou, George N ^a   Theleritis, Christos G ^a   Dikeos, Dimitris G ^a   Psarros, Constantin J ^a   Soldatos, Constantin R ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Amisulpride; Atypical antipsychotics; Metabolic adverse effects; Schizophrenia; Weight gain

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZAMIDE DERIVATIVE; GLUCOSE; INSULIN;

ADULT; AMENORRHEA; ARTICLE; CASE REPORT; DRUG DOSE REGIMEN; DRUG INDUCED DISEASE; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN; HYPERPROLACTINEMIA; MENTAL DISEASE; METABOLIC DISORDER; MONOTHERAPY; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; SCHIZOPHRENIA; SULPIRIDE; TIME FACTORS; WEIGHT GAIN;

EID: 33646696380     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000182119.51672.f0     Document Type: Article

References (29)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999). Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 156:1686-1696.
2. American Diabetes Association (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601.
3. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington DC: American Psychiatric Association.
4. Baptista T, Kin NM, Beaulieu S, de Baptista EA (2002). Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35:205-219.
5. Baptista T, de Baptista EA, Lalonde J, Plamondon J, Kin NM, Beaulieu S, et al. (2004). Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutritient selection. Prog Neuropsychopharmacol Biol Psychiatry 28:1305-1311.
6. Brown S, Birtwistle J, Roe L, Thompson C (1999). The unhealthy lifestyle of people with schizophrenia. Psychol Med 29:697-701.
7. Carriere P, Bonhomme D, Lemperiere T (2000). Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride study group). Eur Psychiatry 15:321-329.
8. Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, et al. (2004). Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 65 (suppl. 7):1-18.
9. Colonna L, Saleem P, Dondey-Nouvel L, Rein W (2000). Long term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int Clin Psychopharmacol 15:13-22.
10. Coulouvrat C, Dondey-Nouvel L (1999). Safety of amisulpride (Solian®): a review of 11 clinical studies. Int Clin Psychopharmacol 14:209-218.
11. Czobor P Volavca J, Sheitman B, Lindermayer J-P, Citrome L, McEvoy J, et al. (2002). Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 22:244-251.
12. Davis JM, Chen N, Glick ID (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553-564.
13. Henderson DC, Cagliero E, Copeland PM, Borba CS, Evins E, Hayden D, et al. (2005). Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 62:19-28.
14. Kay SR, Fizbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schiz Bull 13:261-276.
15. Leucht S, Wagenpfeil S, Hamann J, Kissling W (2004). Amisulpride is an atypical antipsychotic associated with low weight gain. Psychopharmacology 173:112-115.
16. McKeage K, Plosker GL (2004). Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 18:933-956.
17. Melkersson K, Dahl M-L (2004). Adverse metabolic effects associated with atypical antipsychotics. Literature review and clinical implications. Drugs 64:701-723.
18. Meltzer HY, Perry E, Jayathilake K (2002). Clozapine-induced weight gain predicts improvement in psychopathology. Schiz Res 59:19-27.
19. Möller HJ, Boyer P, Fleurot O, Rein W, PROD-ASLP Study Group (1997). Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacology 132:396-401.
20. Mortimer A, Martin S, Loo H, Peuskens J, for the SOLIANOL Study Group (2004). A double-blind, randomized comparative trial of amisulpride versus olanzapine for six months in the treatment of schizophrenia. Int Clin Psychopharmacol 19:63-69.
21. Overall J, Gorham D (1962). The Brief Psychiatric Rating Scale. Psychol Reports 10:149-165.
22. Peuskens J, Bech P, Möller H-J, Bale R, Fleurot O, Rein W, Amisulpride Study Group (1999). Amisulpride versus risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res 88:107-117.
23. Peuskens J, Möller H-J, Puech A (2002). Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur Neuropsychopharmacol 12:305-310.
24. Peuskens J, Lancrenon S, Rein W (2004). Metabolic control in schizophrenic patients treated with atypical antipsychotics: a sub-analysis of a comparative trial of amisulpride and olanzapine. Abstract presented at CINP, June 2004. Paris: CINP.
25. Saleem P, Olié JP, Loo H (2002). Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride. Int Clin Psychopharmacol 17:1-8.
26. Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y, for the Amisulpride Study Group (2002). Amisulpride versus risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology 6:1071-1081.
27. Sussman N (2003). The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol 23 (suppl 1):S21-S26.
28. Taylor DM, McAskill R (2000). Atypical antipsychotics and weight gain - a systematic review. Acta Psych Scand 101:416-432.
29. 2-like antagonist. Psychopharmacology 137:223-232.